Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 10.59
SNTA's Cash to Debt is ranked lower than
57% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. SNTA: 10.59 )
Ranked among companies with meaningful Cash to Debt only.
SNTA' s 10-Year Cash to Debt Range
Min: 2.27  Med: 10.05 Max: N/A
Current: 10.59
F-Score: 3
Z-Score: -5.99
M-Score: -3.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -119.57
SNTA's ROE (%) is ranked lower than
84% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. SNTA: -119.57 )
Ranked among companies with meaningful ROE (%) only.
SNTA' s 10-Year ROE (%) Range
Min: -2635.13  Med: -150.86 Max: -47.15
Current: -119.57
-2635.13
-47.15
ROA (%) -77.54
SNTA's ROA (%) is ranked lower than
79% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. SNTA: -77.54 )
Ranked among companies with meaningful ROA (%) only.
SNTA' s 10-Year ROA (%) Range
Min: -2607.57  Med: -84.24 Max: 108.22
Current: -77.54
-2607.57
108.22
ROC (Joel Greenblatt) (%) -7932.18
SNTA's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. SNTA: -7932.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6515.41  Med: -1413.59 Max: 1600.97
Current: -7932.18
-6515.41
1600.97
Revenue Growth (3Y)(%) -100.00
SNTA's Revenue Growth (3Y)(%) is ranked lower than
97% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SNTA: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNTA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 164.5
Current: -100
0
164.5
EBITDA Growth (3Y)(%) -3.00
SNTA's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. SNTA: -3.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNTA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -29.9  Med: -3.00 Max: 158.9
Current: -3
-29.9
158.9
EPS Growth (3Y)(%) -4.50
SNTA's EPS Growth (3Y)(%) is ranked higher than
52% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. SNTA: -4.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNTA' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.2  Med: 1.00 Max: 166.5
Current: -4.5
-37.2
166.5
» SNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SNTA Guru Trades in Q3 2014

Jim Simons 377,275 sh (New)
Murray Stahl 11,000 sh (unchged)
» More
Q4 2014

SNTA Guru Trades in Q4 2014

Jim Simons 639,581 sh (+69.53%)
Murray Stahl 11,000 sh (unchged)
» More
Q1 2015

SNTA Guru Trades in Q1 2015

Paul Tudor Jones 200,000 sh (New)
Murray Stahl 16,000 sh (+45.45%)
Jim Simons 656,700 sh (+2.68%)
» More
Q2 2015

SNTA Guru Trades in Q2 2015

Murray Stahl 16,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.04
SNTA's P/B is ranked higher than
51% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. SNTA: 4.04 )
Ranked among companies with meaningful P/B only.
SNTA' s 10-Year P/B Range
Min: 2.91  Med: 7.81 Max: 28.34
Current: 4.04
2.91
28.34
Current Ratio 3.09
SNTA's Current Ratio is ranked lower than
61% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. SNTA: 3.09 )
Ranked among companies with meaningful Current Ratio only.
SNTA' s 10-Year Current Ratio Range
Min: 0.43  Med: 3.54 Max: 7.01
Current: 3.09
0.43
7.01
Quick Ratio 3.09
SNTA's Quick Ratio is ranked lower than
57% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SNTA: 3.09 )
Ranked among companies with meaningful Quick Ratio only.
SNTA' s 10-Year Quick Ratio Range
Min: 0.43  Med: 3.54 Max: 7.01
Current: 3.09
0.43
7.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.20
SNTA's Price/Net Cash is ranked higher than
69% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. SNTA: 4.20 )
Ranked among companies with meaningful Price/Net Cash only.
SNTA' s 10-Year Price/Net Cash Range
Min: 3.46  Med: 8.13 Max: 80.9
Current: 4.2
3.46
80.9
Price/Net Current Asset Value 4.04
SNTA's Price/Net Current Asset Value is ranked higher than
68% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. SNTA: 4.04 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SNTA' s 10-Year Price/Net Current Asset Value Range
Min: 3.38  Med: 7.98 Max: 50.56
Current: 4.04
3.38
50.56
Price/Tangible Book 4.04
SNTA's Price/Tangible Book is ranked higher than
58% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. SNTA: 4.04 )
Ranked among companies with meaningful Price/Tangible Book only.
SNTA' s 10-Year Price/Tangible Book Range
Min: 3.07  Med: 6.93 Max: 30.05
Current: 4.04
3.07
30.05
Earnings Yield (Greenblatt) (%) -41.30
SNTA's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. SNTA: -41.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNTA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 45.1  Med: 107.00 Max: 1539.2
Current: -41.3
45.1
1539.2

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 13
EPS($) -0.94 -0.96 -0.97
EPS without NRI($) -0.94 -0.96 -0.97

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:YDO.Germany,
Synta Pharmaceuticals Inc was incorporated in Delware in March 2000 and commenced operations in July 2001. It is a biopharmaceutical company engaged in research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Its drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in development program, including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, it is developing several candidates from its proprietary Hsp90 inhibitor Drug Conjugate program (HDC Program), which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver an array of anti-cancer payloads. It also has an additional clinical-stage oncology candidate: elesclomol, a mitochondrial metabolism inhibitor. Its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. Its patent portfolio has a total of 867 patents and patent applications.
» More Articles for SNTA

Headlines

Articles On GuruFocus.com
Stocks Both Gurus and Company Insiders Are Buying Jun 18 2015 
Insider Buys: FULL, FMI and SNTA Apr 10 2015 
Weekly 3-Year Low Highlights: NSR, ELRC, PLPC, SNTA Feb 16 2015 
5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 08 2015 
5-year lows: Synta Pharmaceuticals Inc, Rex Energy Corp, Petroquest Energy Inc, and Liquidity Servic Jan 11 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
Guidance & Quarterly Review on Four Biotech Companies Aug 14 2015
SYNTA PHARMACEUTICALS CORP Financials Aug 13 2015
10-Q for Synta Pharmaceuticals Corp. Aug 09 2015
Edited Transcript of SNTA earnings conference call or presentation 6-Aug-15 2:00pm GMT Aug 07 2015
Synta's Q2 Loss Narrower than Expected, Focus on Pipeline - Analyst Blog Aug 07 2015
Synta Pharmaceuticals Corp Earnings Call scheduled for 10:00 am ET today Aug 06 2015
Synta (SNTA) Reports Narrower-than-Expected Q2 Loss - Tale of the Tape Aug 06 2015
Synta reports 2Q loss Aug 06 2015
Synta reports 2Q loss Aug 06 2015
Q2 2015 Synta Pharmaceuticals Corp Earnings Release - Before Market Open Aug 06 2015
Synta Reports Second Quarter 2015 Financial Results Aug 06 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report Aug 06 2015
What to Expect from Synta (SNTA) this Earnings Season? - Analyst Blog Aug 03 2015
Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015 Jul 30 2015
Synta Reports Encouraging Preclinical Data on Ganetespib - Analyst Blog Jun 24 2015
Synta Announces Journal Publication Describing Complementary Activity of Hsp90 Inhibition and Immune... Jun 23 2015
Synta to Participate in Upcoming Investor Conferences Jun 16 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 15 2015
Synta Announces Ganetespib Program Updates Jun 02 2015
Synta Announces Presentations at the 2015 ASCO Annual Meeting May 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK